HRP20130910T1 - Kondenzirani aminopiridin kao inhibitori hsp90 - Google Patents

Kondenzirani aminopiridin kao inhibitori hsp90 Download PDF

Info

Publication number
HRP20130910T1
HRP20130910T1 HRP20130910AT HRP20130910T HRP20130910T1 HR P20130910 T1 HRP20130910 T1 HR P20130910T1 HR P20130910A T HRP20130910A T HR P20130910AT HR P20130910 T HRP20130910 T HR P20130910T HR P20130910 T1 HRP20130910 T1 HR P20130910T1
Authority
HR
Croatia
Prior art keywords
substituted
unsubstituted
alkyl
cancer
aryl
Prior art date
Application number
HRP20130910AT
Other languages
English (en)
Croatian (hr)
Inventor
Xiong Cai
Changgeng Qian
Haixiao Zhai
Original Assignee
Curis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis, Inc. filed Critical Curis, Inc.
Publication of HRP20130910T1 publication Critical patent/HRP20130910T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20130910AT 2007-03-20 2008-03-10 Kondenzirani aminopiridin kao inhibitori hsp90 HRP20130910T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89592107P 2007-03-20 2007-03-20
US1528807P 2007-12-20 2007-12-20
PCT/US2008/056396 WO2008115719A1 (en) 2007-03-20 2008-03-10 Fused amino pyridine as hsp90 inhibitors

Publications (1)

Publication Number Publication Date
HRP20130910T1 true HRP20130910T1 (hr) 2013-10-25

Family

ID=39766345

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130910AT HRP20130910T1 (hr) 2007-03-20 2008-03-10 Kondenzirani aminopiridin kao inhibitori hsp90

Country Status (24)

Country Link
US (10) US8324240B2 (cg-RX-API-DMAC7.html)
EP (1) EP2069324B1 (cg-RX-API-DMAC7.html)
JP (1) JP5401329B2 (cg-RX-API-DMAC7.html)
KR (1) KR101313804B1 (cg-RX-API-DMAC7.html)
CN (1) CN101679347B (cg-RX-API-DMAC7.html)
AU (1) AU2008229216B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808301B1 (cg-RX-API-DMAC7.html)
CA (1) CA2680778C (cg-RX-API-DMAC7.html)
CY (1) CY1114507T1 (cg-RX-API-DMAC7.html)
DK (1) DK2069324T3 (cg-RX-API-DMAC7.html)
EA (1) EA019103B1 (cg-RX-API-DMAC7.html)
ES (1) ES2430217T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130910T1 (cg-RX-API-DMAC7.html)
IL (2) IL200924A (cg-RX-API-DMAC7.html)
MX (1) MX2009009936A (cg-RX-API-DMAC7.html)
MY (1) MY148860A (cg-RX-API-DMAC7.html)
NZ (1) NZ579635A (cg-RX-API-DMAC7.html)
PL (1) PL2069324T3 (cg-RX-API-DMAC7.html)
PT (1) PT2069324E (cg-RX-API-DMAC7.html)
RS (1) RS52978B (cg-RX-API-DMAC7.html)
SI (1) SI2069324T1 (cg-RX-API-DMAC7.html)
TW (1) TWI471131B (cg-RX-API-DMAC7.html)
WO (1) WO2008115719A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200906371B (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
ES2645095T3 (es) * 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
BRPI0808301B1 (pt) * 2007-03-20 2022-05-03 Curis, Inc Composto e composição farmacêutica
US20080234297A1 (en) * 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
EP2469399B1 (en) 2008-02-11 2019-09-11 Idean Enterprises Oy Layer-based user interface
US8017780B1 (en) 2008-10-09 2011-09-13 Myrexis, Inc. Therapeutic compounds and uses thereof
MX2011007612A (es) * 2009-01-16 2012-01-20 Curis Inc Aminopiridinas fusionadas para el tratamiento de tumores del cerebro.
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
PL2452940T3 (pl) * 2009-07-10 2015-05-29 Taiho Pharmaceutical Co Ltd Związek azabicykliczny i jego sól
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
AU2013204109B2 (en) * 2009-10-07 2016-05-05 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
WO2011044394A1 (en) * 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
EP2542687A1 (en) * 2010-03-05 2013-01-09 Baylor Research Institute Involvement of androgen/androgen receptor pathway in fabry disease
WO2012131413A1 (en) 2011-03-25 2012-10-04 Debiopharm Sa Crystalline forms of fused amino pyridines as hsp90 inhibitors
CA2832530C (en) 2011-04-05 2021-02-16 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
US9546170B2 (en) 2011-04-05 2017-01-17 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EP2701702B1 (en) * 2011-04-26 2016-11-30 Rdd Pharma Ltd. Oxymetazoline for the treatment of ano-rectal disorders
US9422320B2 (en) 2012-02-09 2016-08-23 University Of Kansas C-terminal HSP90 inhibitors
US9533002B2 (en) 2012-05-25 2017-01-03 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
EA201690406A1 (ru) * 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения
KR102325454B1 (ko) 2013-12-23 2021-11-16 메모리얼 슬로안 케터링 캔서 센터 방사성표지화를 위한 방법 및 시약
WO2015188198A2 (en) 2014-06-06 2015-12-10 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
NZ728482A (en) * 2014-06-24 2022-11-25 Univ Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
KR20170052687A (ko) 2014-09-17 2017-05-12 메모리얼 슬로안-케터링 캔서 센터 Ｈｓｐ90-표적화된 염증 및 감염 영상화 및 치료
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
JP6756925B2 (ja) 2017-01-11 2020-09-16 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼの二環式阻害剤
ES2788856T3 (es) 2017-03-20 2020-10-23 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
EP3600376A1 (en) * 2017-03-31 2020-02-05 Alma Bio Therapeutics Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same
SMT202200232T1 (it) 2017-08-07 2022-07-21 Alkermes Inc Inibitori biciclici di istone deacetilasi
EP3794009A1 (en) 2018-05-14 2021-03-24 Reata Pharmaceuticals, Inc. Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors
MA57202B1 (fr) 2019-09-19 2025-09-30 Novo Nordisk Health Care Ag Compositions d'activation de la pyruvate kinase r (pkr)
GB202006382D0 (en) 2020-04-30 2020-06-17 Spermatech As Use
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023006993A1 (en) 2021-07-30 2023-02-02 Atmosr Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome
AU2023356671A1 (en) * 2022-10-06 2025-04-24 Regranion, Llc Methods and compositions for treating hidradenitis suppurativa
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025014551A1 (en) * 2023-07-10 2025-01-16 Regranion, Llc Methods and compositions for treating atopic dermatitis
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080629A1 (en) * 2023-10-10 2025-04-17 Regranion, Llc Methods and compositions for treating behçet's disease
WO2025080645A1 (en) * 2023-10-10 2025-04-17 Regranion, Llc Methods and compositions for treating bullous pemphigoid
WO2025080623A1 (en) * 2023-10-10 2025-04-17 Regranion, Llc Methods and compositions for treating discoid lupus erythematosus, systemic lupus erythematosus, and subacute cutaneous lupus erythematosus
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217284A1 (en) * 2024-04-09 2025-10-16 Regranion, Llc Methods and compositions for treating inflammatory and autoimmune disorders of the skin
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0708772T3 (da) * 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
US5644063A (en) * 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US6723727B1 (en) * 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
DE69934093T2 (de) * 1998-01-27 2007-06-21 Aventis Pharmaceuticals Inc. SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
JP4324338B2 (ja) 1999-07-02 2009-09-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合イミダゾール化合物及び糖尿病治療薬
HK1054227A1 (zh) * 1999-07-28 2003-11-21 阿温蒂斯药物制品公司 取代的氧代氮杂杂环基化合物
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
JP2005519848A (ja) * 2000-11-02 2005-07-07 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
WO2004072080A1 (en) * 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2004253543B2 (en) * 2003-07-01 2009-02-19 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
BRPI0414533A (pt) * 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
CA2578975A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
EP1874769B1 (de) * 2005-04-25 2011-09-14 Merck Patent GmbH Neuartige aza-heterozyklen als kinase-inhibitoren
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
CA2634723A1 (en) * 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
US20070253896A1 (en) * 2006-02-07 2007-11-01 Conforma Therapeutics Corporation 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors
CA2640672A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
CA2652263A1 (en) * 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
CN101573333B (zh) 2006-10-28 2013-06-12 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US20080234297A1 (en) * 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
BRPI0808301B1 (pt) * 2007-03-20 2022-05-03 Curis, Inc Composto e composição farmacêutica
MX2011007612A (es) 2009-01-16 2012-01-20 Curis Inc Aminopiridinas fusionadas para el tratamiento de tumores del cerebro.

Also Published As

Publication number Publication date
US20230192687A1 (en) 2023-06-22
EA200901263A1 (ru) 2010-02-26
CN101679347B (zh) 2014-10-22
EA019103B1 (ru) 2014-01-30
PL2069324T3 (pl) 2014-01-31
US10844056B2 (en) 2020-11-24
ZA200906371B (en) 2010-05-26
WO2008115719A9 (en) 2009-02-26
US9630965B2 (en) 2017-04-25
US11560377B2 (en) 2023-01-24
CN101679347A (zh) 2010-03-24
NZ579635A (en) 2011-07-29
AU2008229216A1 (en) 2008-09-25
BRPI0808301B1 (pt) 2022-05-03
CA2680778A1 (en) 2008-09-25
US20160058742A1 (en) 2016-03-03
AU2008229216B2 (en) 2013-03-21
CA2680778C (en) 2016-05-10
JP2010522184A (ja) 2010-07-01
MY148860A (en) 2013-06-14
JP5401329B2 (ja) 2014-01-29
IL200924A (en) 2015-02-26
KR20100015739A (ko) 2010-02-12
US20080234314A1 (en) 2008-09-25
US9402832B2 (en) 2016-08-02
HK1131986A1 (en) 2010-02-12
US20120237508A1 (en) 2012-09-20
US20170267674A1 (en) 2017-09-21
US20140221343A1 (en) 2014-08-07
WO2008115719A1 (en) 2008-09-25
IL236938A0 (en) 2015-03-31
US9040556B2 (en) 2015-05-26
KR101313804B1 (ko) 2013-10-01
EP2069324A4 (en) 2011-09-07
ES2430217T3 (es) 2013-11-19
CY1114507T1 (el) 2016-10-05
TWI471131B (zh) 2015-02-01
IL200924A0 (en) 2010-05-17
DK2069324T3 (da) 2013-09-02
US20200062754A1 (en) 2020-02-27
US10428068B2 (en) 2019-10-01
MX2009009936A (es) 2010-02-11
US20190010152A1 (en) 2019-01-10
US10035797B2 (en) 2018-07-31
US8324240B2 (en) 2012-12-04
US8586605B2 (en) 2013-11-19
TW200845967A (en) 2008-12-01
PT2069324E (pt) 2013-10-10
EP2069324B1 (en) 2013-07-31
EP2069324A1 (en) 2009-06-17
US20210292317A1 (en) 2021-09-23
RS52978B (sr) 2014-02-28
US20170002002A1 (en) 2017-01-05
BRPI0808301A2 (pt) 2013-08-06
SI2069324T1 (sl) 2013-10-30

Similar Documents

Publication Publication Date Title
HRP20130910T1 (hr) Kondenzirani aminopiridin kao inhibitori hsp90
PH12018500940A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
HRP20161367T1 (hr) Spojevi reverznog amida kao inhibitori protein deacetilaze i postupci za njihovu uporabu
IL189069A0 (en) Piperidine and piperazine derivatives as p2x3 antagonists
HRP20120762T1 (hr) Tetrasupstituirani piridazini kao inhibitori hedgehog puta
MX2014006210A (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
AR070136A1 (es) Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa
PE20110387A1 (es) Aminotriazolo-piridinas como inhibidores de cinasa
MX2010000658A (es) Derivados de pirimidina 934.
RU2013138717A (ru) Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе
HRP20140437T1 (hr) Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora
HRP20170303T1 (hr) Derivat piridona
KR20180011759A (ko) 타겟화된 단백질들의 향상된 분해를 위한 화합물들 및 방법들
PH12012501535A1 (en) Substituted naphthyridines and their use as syk kinase inhibitors
IN2014DN01993A (cg-RX-API-DMAC7.html)
MX369801B (es) Compuesto heterociclico sustituido con halogeno.
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
GB2544905A (en) Synthesis and use of amino lipids
JP2015535851A5 (cg-RX-API-DMAC7.html)
MX2009008509A (es) Compuesto de anillo puenteado-aza.
PH12014500775A1 (en) Ethynyl derivatives as mglur5 allosteric modulators
HRP20180973T1 (hr) Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora
PH12016500427A1 (en) Ethynyl derivatives
HRP20160465T1 (hr) Novi supstituirani derivati izokinolina
DE602004012400D1 (de) N-ä(piperazinyl)hetarylüarylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor